

BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

| | |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Company | 2022/01/25 17:27:10 |
|  | Price 61.88 USD |
| | Difference  -1.17%(-0.73) |



| |
|-------------------------------------------------------------------------------|
| Contact Details |
| BRISTOL MYERS SQUIBB CO. Tel: 1-212-546-4000 |
| -- Fax: - |
| 430 East 29th Street Web: http://www.bms.com |
| 10016 New York E-mail: - |

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2020 | | 2019 | | 2018 | |
|---------------------------------------|-----------------|------------------------|-----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 30,192,000,000 | | 29,354,000,000 | | 17,160,000,000 | |
| Common stock capital | | 292,000,000 | | 292,000,000 | | 221,000,000 |
| Fixed assets | 88,289,000,000 | | 100,590,000,000 | | 17,826,000,000 | |
| Equity capital of a company | | 37,882,000,000 | | 51,698,000,000 | | 14,127,000,000 |
| Cash and cash equivalents | 14,635,000,000 | | 12,346,000,000 | | 6,911,000,000 | |
| Accrued liabilities | | 899,000,000 | | 725,000,000 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 19,080,000,000 | | 18,304,000,000 | | 10,654,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 61,519,000,000 | | 59,942,000,000 | | 10,205,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 6,044,000,000 | | 8,704,000,000 | | 4,559,000,000 |
| Total assets | 118,481,000,000 | 118,481,000,000 | 129,944,000,000 | 129,944,000,000 | 34,986,000,000 | 34,986,000,000 |

Balance notes

| | 2020 | 2019 | 2018 |
|----------------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 30,250 | 30,000 | 23,300 |
| Equity ratio | 32.02% | 39.86% | 40.65% |
| Debt-equity ratio | 212.27% | 150.87% | 145.98% |

Others

| | 2020 | 2019 | 2018 |
|-------------------------|---------|--------|--------|
| Tax Expense Rate | -30.91% | 30.45% | 17.11% |

BRISTOL-MYERS SQUIBB CO.

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

Income statement

| | 2020 | 2019 | 2018 |
|---------------------------------------------------------------|----------------|----------------|----------------|
| Turnover | 42,518,000,000 | 26,145,000,000 | 22,561,000,000 |
| Net income | -9,015,000,000 | 3,439,000,000 | 4,920,000,000 |
| EBIT | -4,912,275,200 | 4,555,227,200 | 5,270,204,800 |
| Operating income before taxes | -6,871,000,000 | 4,975,000,000 | 5,968,000,000 |
| Cash Flow | 14,052,000,000 | 8,067,000,000 | 5,940,000,000 |
| Net interest income | -1,299,000,000 | -192,000,000 | -10,000,000 |
| Research and development expenses | 9,557,000,000 | 5,949,000,000 | 5,131,000,000 |
| Income taxes | 2,124,000,000 | 1,515,000,000 | 1,021,000,000 |
| Result from investments in subsidiaries, associates and other | - | - | - |
| Revenues per employee | 1,239,136 | 768,314 | 853,639 |

Board of Directors

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Julia Haller | Member of Board of Directors |
| Karen Vousden | Member of Board of Directors |
| Manuel Hidalgo Medina | Member of Board of Directors |
| Derica Rice | Member of Board of Directors |
| Gerald Storch | Member of Board of Directors |
| Paula Price | Member of Board of Directors |
| Peter Arduini | Member of Board of Directors |
| Phyllis Yale | Member of Board of Directors |
| Theodore Samuels | Member of Board of Directors |
| Giovanni Caforio | Chairman of Managing Board |
| Christopher Boerner | Member of Executive Committee |
| Adam Dubow | Member of Executive Committee |
| Ann M. Powell | Member of Executive Committee |
| Catalina Vargas | Member of Executive Committee |
| David Elkins | Member of Executive Committee |
| Elizabeth A. Mily | Member of Executive Committee |
| Lou Schmukler | Member of Executive Committee |
| Michelle Weese | Member of Executive Committee |
| Paul von Autenried | Member of Executive Committee |
| Rupert Vessey | Member of Executive Committee |
| Samit Hirawat | Member of Executive Committee |
| Sandra Leung | Member of Executive Committee |